Coverage appeal AI
Counterforce Health
Counterforce Health offers free assistance with a patient’s chosen coverage-denial challenge. The policy discloses secondary data use. Patient control over final wording, evidence checking, submission, and training use remains incompletely verified.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 84 out of 100 toward patient-directed
Counterforce Health offers free assistance with a patient’s chosen coverage-denial challenge. The policy discloses secondary data use. Patient control over final wording, evidence checking, submission, and training use remains incompletely verified.
Potentially agency-expanding, with AI-training and verification caveats
Counterforce Health offers free assistance with a patient’s chosen coverage-denial challenge. The policy discloses secondary data use. Patient control over final wording, evidence checking, submission, and training use remains incompletely verified.
Patient agency
How this tool changes agency
assistance can reduce the work required to oppose a coverage decision. It remains unclear how well patients can inspect the argument's evidence, compare alternatives, or challenge the system itself. An advocacy mission does not demonstrate those capacities.
Final submission authority, evidence traceability, output-use terms, training opt-out, and the reach of deletion.
Patient agency assessment
Who sets and changes the goal?
the individual service is directed toward a patient's chosen denial challenge. The baseline describes drafts that patients submit, but this pass did not establish an enforced final-approval gate, broad goal redirection, or independent output-use rights. Keep correction as partial rather than upgrading it from the marketing.
What can the patient understand, question, or do?
assistance can reduce the work required to oppose a coverage decision. It remains unclear how well patients can inspect the argument's evidence, compare alternatives, or challenge the system itself. An advocacy mission does not demonstrate those capacities.
Can the patient evaluate the conditions of use?
training disclosure makes a consequential practice visible, while the scope of patient choice over that practice remains uncertain. This supports the existing caveat. It is not evidence that every patient's information is used in training.
Text findings
Conditions of use
Published controls and their limits
training disclosure makes a consequential practice visible, while the scope of patient choice over that practice remains uncertain. This supports the existing caveat. It is not evidence that every patient's information is used in training.
What remains unknown?
Not tested or not established
Final submission authority, evidence traceability, output-use terms, training opt-out, and the reach of deletion.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Final submission authority, evidence traceability, output-use terms, training opt-out, and the reach of deletion. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Medium for published documentation, low for implementation (AI-assisted draft)